record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; placebo-controlled clinical trial where source reports control arm · Homo sapiens
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; placebo-controlled clinical trial where source reports control arm
evidence type
experimental
species
Homo sapiens
evidence spans
Verubecestat APECS trial in prodromal AD also failed; cognitive worsening replicated in the earlier-stage population. Class concern about BACE1 inhibitor cognitive harm — likely off-target via non-APP BACE1 substrates (e.g. neuregulin-1, seizure protein 6).
Michael Egan; James Kost; Tiffini Voss; Yuki Mukai; Paul Aisen; Jeffrey L. Cummings; Pierre N. Tariot; Bruno Vellas. New England Journal of Medicine 2019. doi:10.1056/NEJMoa1812840 · curator_source · 10.1056/NEJMoa1812840
conditions
Provenance
source title
Michael Egan; James Kost; Tiffini Voss; Yuki Mukai; Paul Aisen; Jeffrey L. Cummings; Pierre N. Tariot; Bruno Vellas. New England Journal of Medicine 2019. doi:10.1056/NEJMoa1812840
doi
10.1056/NEJMoa1812840
pmid
30970186
journal
New England Journal of Medicine
authors
Michael Egan, James Kost, Tiffini Voss, Yuki Mukai, Paul Aisen, Jeffrey L. Cummings, Pierre N. Tariot, Bruno Vellas
source record
declaredvs_5267252f5625711bdoi:10.1056/NEJMoa1812840 · 10.1056/NEJMoa1812840
inspect source →
source record
declaredvs_a8e8c2eb2c0cc3c9doi:10.1056/NEJMoa1812840 · 10.1056/NEJMoa1812840 · 30970186
inspect source →
Verubecestat APECS trial in prodromal AD also failed; cognitive worsening replicated in the earlier-stage population. Class concern about BACE1 inhibitor cognitive harm — likely off-target via non-APP BACE1 substrates (e.g. neuregulin-1, seizure protein 6).
vs_a8e8c2eb2c0cc3c9 · source:Michael Egan; James Kost; Tiffini Voss; Yuki Mukai; Paul Aisen; Jeffrey L. Cummings; Pierre N. Tariot; Bruno Vellas. New England Journal of Medicine 2019. doi:10.1056/NEJMoa1812840|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_e9f2a28ca4fa2c24finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_f2b468ec2f316fdffinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.